KLK3 and bone metastasis: We propose that the optimal cut-off value for TTN be >11 months for advanced PCa patients without bone metastasis and >8 months for those with bone metastasis in both groups with ≤0.2 PSA nadir and >0.2 with and without metastasis, respectively, for progression-free survival [6].